- Home
- QXL vs RNXT Comparison
QXL vs RNXT Comparison
Compare QXL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXL | RNXT |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.6M | 79.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QXL | RNXT |
|---|---|---|
| Price | $5.60 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 62.4K | ★ 1.4M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $26,941,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $57.00 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $4.05 | $0.70 |
| 52 Week High | $7.70 | $2.59 |
Technical Indicators
Market Signals| Indicator | QXL | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 51.22 |
| Support Level | $4.09 | $0.83 |
| Resistance Level | N/A | $2.59 |
| Average True Range (ATR) | 0.35 | 0.26 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 74.87 | 13.46 |
Price Performance
Historical ComparisonAbout QXL Quantum X Labs Inc. Common Stock
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.